Liver Fibrosis in NAFLD: future diagnostic biomarkers and anti-fibrotic drugs

In this review, L. J. M. Heyens et al. (Hasselt University, Belgium, Maastricht University, Netherlands, and, Ziekenhuis Oost-Limburg, Belgium) give an overview of the pathogenic mechanisms of the evolution from isolated steatosis to fibrosis. The authors also discuss of the current and future diagnostic biomarkers and anti-fibrotic drugs...
PUBLISHED IN: Front Med (Lausanne) 2021

Commentary

In this review, L. J. M. Heyens et al. (Hasselt University, Belgium, Maastricht University, Netherlands, and, Ziekenhuis Oost-Limburg, Belgium) give an overview of the pathogenic mechanisms of the evolution from isolated steatosis to fibrosis. The authors also discuss of the current and future diagnostic biomarkers and anti-fibrotic drugs.

Share the article
Dr. G. Bozet, MD

Dr. G. Bozet, MD

Articles: 173

Leave a Reply

Your email address will not be published.

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES